292 related articles for article (PubMed ID: 9154166)
1. New agents for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet RA; Doody LA; Malone WF; Hawk ET; Sigman CC
J Cell Biochem Suppl; 1996; 26():1-28. PubMed ID: 9154166
[TBL] [Abstract][Full Text] [Related]
2. Chemopreventive drug development: perspectives and progress.
Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Sigman CC
Cancer Epidemiol Biomarkers Prev; 1994; 3(1):85-98. PubMed ID: 8118391
[TBL] [Abstract][Full Text] [Related]
3. Strategy and planning for chemopreventive drug development: clinical development plans II.
Kelloff GJ; Crowell JA; Hawk ET; Steele VE; Lubet RA; Boone CW; Covey JM; Doody LA; Omenn GS; Greenwald P; Hong WK; Parkinson DR; Bagheri D; Baxter GT; Blunden M; Doeltz MK; Eisenhauer KM; Johnson K; Knapp GG; Longfellow DG; Malone WF; Nayfield SG; Seifried HE; Swall LM; Sigman CC
J Cell Biochem Suppl; 1996; 26():54-71. PubMed ID: 9154168
[TBL] [Abstract][Full Text] [Related]
4. Progress in cancer chemoprevention.
Kelloff GJ; Crowell JA; Steele VE; Lubet RA; Boone CW; Malone WA; Hawk ET; Lieberman R; Lawrence JA; Kopelovich L; Ali I; Viner JL; Sigman CC
Ann N Y Acad Sci; 1999; 889():1-13. PubMed ID: 10668477
[TBL] [Abstract][Full Text] [Related]
5. Cancer chemoprevention. Part 2: Hormones, nonclassic antioxidant natural agents, NSAIDs, and other agents.
Singh DK; Lippman SM
Oncology (Williston Park); 1998 Dec; 12(12):1787-800; discussion 1802, 1805. PubMed ID: 9874850
[TBL] [Abstract][Full Text] [Related]
6. Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute.
Kelloff GJ; Crowell JA; Boone CW; Steele VE; Lubet RA; Greenwald P; Alberts DS; Covey JM; Doody LA; Knapp GG
J Cell Biochem Suppl; 1994; 20():55-62. PubMed ID: 7616753
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic considerations in chemopreventive drug development.
Kelloff GJ; Boone CW; Steele VE; Fay JR; Lubet RA; Crowell JA; Sigman CC
J Cell Biochem Suppl; 1994; 20():1-24. PubMed ID: 7616736
[TBL] [Abstract][Full Text] [Related]
8. Chemoprevention clinical trials.
Kelloff GJ; Boone CW; Malone WF; Steele VE
Mutat Res; 1992 Jun; 267(2):291-5. PubMed ID: 1376431
[TBL] [Abstract][Full Text] [Related]
9. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
10. A quantitative angiogenesis model for efficacy testing of chemopreventive agents.
Sharma S; Ghoddoussi M; Gao P; Kelloff GJ; Steele VE; Kopelovich L
Anticancer Res; 2001; 21(6A):3829-37. PubMed ID: 11911254
[TBL] [Abstract][Full Text] [Related]
11. Cancer chemoprevention. Part 1: Retinoids and carotenoids and other classic antioxidants.
Singh DK; Lippman SM
Oncology (Williston Park); 1998 Nov; 12(11):1643-53, 1657-8; discussion 1659-60. PubMed ID: 9834941
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention trials and surrogate end point biomarkers in the cervix.
Mitchell MF; Hittelman WK; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Wharton JT; Hong WK
Cancer; 1995 Nov; 76(10 Suppl):1956-77. PubMed ID: 8634987
[TBL] [Abstract][Full Text] [Related]
13. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents.
Kelloff GJ; Crowell JA; Steele VE; Lubet RA; Malone WA; Boone CW; Kopelovich L; Hawk ET; Lieberman R; Lawrence JA; Ali I; Viner JL; Sigman CC
J Nutr; 2000 Feb; 130(2S Suppl):467S-471S. PubMed ID: 10721931
[TBL] [Abstract][Full Text] [Related]
14. Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment.
Armstrong WB; Wan XS; Kennedy AR; Taylor TH; Meyskens FL
Laryngoscope; 2003 Oct; 113(10):1687-702. PubMed ID: 14520092
[TBL] [Abstract][Full Text] [Related]
15. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer.
Kelloff GJ; Lieberman R; Steele VE; Boone CW; Lubet RA; Kopelovich L; Malone WA; Crowell JA; Higley HR; Sigman CC
Urology; 2001 Apr; 57(4 Suppl 1):46-51. PubMed ID: 11295594
[TBL] [Abstract][Full Text] [Related]
16. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention of cancer.
Szarka CE; Grana G; Engstrom PF
Curr Probl Cancer; 1994; 18(1):6-79. PubMed ID: 8005001
[TBL] [Abstract][Full Text] [Related]
18. Multiagent chemopreventive agent combinations.
Brenner DE
J Cell Biochem Suppl; 2000; 34():121-4. PubMed ID: 10762024
[TBL] [Abstract][Full Text] [Related]
19. Cancer prevention by protease inhibitors.
Kennedy AR
Prev Med; 1993 Sep; 22(5):796-811. PubMed ID: 8234219
[TBL] [Abstract][Full Text] [Related]
20. Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI Chemoprevention Drug Development Program.
Steele VE; Moon RC; Lubet RA; Grubbs CJ; Reddy BS; Wargovich M; McCormick DL; Pereira MA; Crowell JA; Bagheri D
J Cell Biochem Suppl; 1994; 20():32-54. PubMed ID: 7616752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
